Actively Recruiting
Study of Sintilimab Plus SOX Versus SOX Alone as Additional Treatment for Advanced Stage Gastric or Gastroesophageal Junction Adenocarcinoma
Led by Fudan University · Updated on 2026-03-25
276
Participants Needed
1
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining sintilimab with SOX chemotherapy compared to SOX chemotherapy alone as adjuvant treatment for patients with stage pIIIC or dMMRMSI-H pIIIAIIIB gastric or gastroesophageal junction adenocarcinoma. This phase II, randomized controlled trial aims to improve 3-year disease-free survival in this patient group. The study also examines overall survival and treatment safety. Participants will be randomly assigned to one of two groups one receiving up to 8 cycles of sintilimab combined with SOX chemotherapy, and the other receiving SOX chemotherapy alone. Sintilimab is given intravenously at 200 mg every 3 weeks, while SOX consists of oral S-1 tablets twice daily for 14 days plus intravenous oxaliplatin every 3 weeks. Tumor imaging assessments are performed regularly to monitor disease status. During the study, participants undergo regular imaging scans every 12 weeks for up to 24 months, then every 24 weeks afterward, using the same technique throughout. Safety is monitored from the first treatment until 30 days after the last dose. The primary outcome is 3-year disease-free survival, with additional assessments of overall survival and adverse events. The total participation duration may extend up to 7 years for survival follow-up.
CONDITIONS
Brief Title
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Research Team
X
Xiaowen Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here